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image outcome than the surgically treated OCC patients. 
Education was also an independent factor for BIS. In OCC 
patients, facial skin sacrificed, mouth angle sacrificed, 
maxillectomy, and mandibulectomy were significantly 
associated with BIS. Using multivariate analysis, inferior 
maxillectomy and segmental mandibulectomy were the 
independent poor prognosticators of body image outcome in 
OCC patients. 
 
Conclusion: The radical surgery for head and neck cancer 
patients has a significant impact on body image, especially 
those with facial bone destruction. These findings could be 
used to guide psychosocial interventions targeting body 
image disturbance for patients with head and neck cancer. 
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Purpose or Objective: Head and neck cancer patients 
treated with chemoradiation are at risk for developing 
trismus (reduced mouth opening). Trismus is often a 
persisting side-effect and difficult to manage. It impairs 
eating, speech and oral hygiene, affecting quality of life. 
Although several studies identified the masseter muscle (MM) 
as one of the main organs at risk, currently this structure is 
rarely considered during treatment planning. Prospective 
studies for chemoradiation are lacking. The aim of our study 
was to quantify the relationship between radiation dose to 
the MM and development of radiation-induced trismus in an 
IMRT-VMAT population. 
 
Material and Methods: The 93 patients in this study 
participated in a prospective preventive exercise program to 
preserve oral functioning between 2006-2013. All received 
concomitant high-dose chemotherapy during VMAT- or IMRT-
radiotherapy (70 Gy in 35 fractions). Tumor locations were 
mainly oropharynx (37%) and hypopharynx (33%). Maximum 
interincisor mouth opening was measured before and 
approximately 10 weeks after the end of treatment. Bilateral 
delineations of the MM were available from 2 retrospective 
studies. Patients were excluded if trismus was present at 
baseline, or if gross tumor infiltration of the MM was present 
on CT evaluation. Evaluated outcomes were trismus (mouth 
opening ≤ 35 mm) and decrease in mouth opening. Logistic 
regression (using maximum likelihood) was performed. 
 
Results: At the first evaluation, 6-12 weeks post-treatment, 
fourteen patients had developed radiation-induced trismus 
(15%). On average, mouth opening decreased with 4.1 mm, or 
8.2 % relative to baseline. Mean dose to the ipsilateral MM 
was a stronger predictor for trismus than mean dose to the 
contralateral MM, as indicated by the lowest -2 log likelihood 
(Table 1). Figure 1A shows the correlation between the 
ipsilateral mean masseter dose and the relative decrease in 
mouth opening, with trismus cases indicated in red. No 
trismus cases were observed in 33 patients (35%) with a mean 
dose to the ipsilateral MM < 20 Gy. The risk of trismus in the 
other 60 patients (65%) increased with higher mean doses to 
the ipsilateral MM. Figure 1B shows the fitted NTCP curve as 
a function of the mean dose, with a TD50 of 55 Gy. The 
actual incidence (with 1 SE) of trismus cases within 5 dose 
bins is indicated as well, showing a good correspondence with 
the NTCP fit with a relatively large uncertainty in the dose 
area > 50 Gy. Patients with tumors located in the oropharynx 
were at highest risk. 
 
Conclusion: The risk of trismus can be established with the 
mean dose to the ipsilateral masseter muscle. The majority 
of head and neck cancer patients could benefit from dose 
reduction to the masseter muscles to prevent trismus, 
especially patients with a mean dose to the ipsilateral 
masseter > 20 Gy. Further development of a NTCP model 
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Purpose or Objective: Oral mucositis (OM) is the most 
frequent and severe acute toxicity of chemoradiotherapy 
(CRT) in head and neck cancer (HNC) patients. In preclinical 
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studies, topical clonidine shown activity in reducing NF-κB 
activation and incidence of severe OM (SOM). In a randomized 
double blind, placebo-controlled study, a novel 
mucoadhesive buccal tablet (MBT) containing clonidine 
reduced the incidence of SOM in HNC patients being treated 
with CRT. We now report overall survival (OS), tolerability 
and systemic exposure of clonidine of study subjects. 
 
Material and Methods: Clonidine MBT 50µg (n=56), 100µg 
(n=65) or matching placebo (n=62) were applied to the gum 
once daily 1-3 days prior to RT and then daily until the end of 
CRT (1.8-2.2 Gy/d, 5 times/week combined with a platinum 
based CT). AEs, vital signs and gingival tolerance by Silness-
Loe index (global score from 0 to 9) were assessed twice a 
week; xerostomia and sedation (visual scale from 0 to 10) 
were evaluated once a week. Blood and saliva samples for 
clonidine levels were collected Q2 weeks. OS data will be 
collected until 2 years after last patient last visit. Patients 
received a median cumulative radiation dose of 66 Gy [min: 
4; max: 78]. SOM was reported in 60% [95%CI: 47%; 72%] of 
placebo patients, 43% [95%CI: 29%; 57%] in clonidine 50µg 
MBT (p=0.063) and 48 % [95%CI: 35%; 61%] in clonidine 100µg 
MBT (p=0.169). 
 
Results: All grade AE incidence was 91% in clonidine MBT 
groups and 98% in placebo group (p<0.10). No difference in 
heart rate and blood pressure was reported between groups. 
Reversible hypotension AEs were reported in 7% clonidine 
MBT 50µg patients, 6% clonidine MBT 100μg and 2% placebo-
treated patients (p=ns). Sedation score slightly increased in 
all groups between week 1 and week 6 (overall from 1.5 ± 2.3 
to 3.0 ±2.3) and was similar between groups (p=ns). 
Xerostomia grade ≥ 2 increased to 41% in clonidine MBT 50µg, 
31% in clonidine MBT 100µg and 42% in placebo patients 
(p=ns). The mean plasma/saliva concentrations of clonidine 
were 0.087/154.2ng/mL in clonidine MBT 50µg and 
0.134/301.1 ng/mL in clonidine MBT 100µg. With a median 
follow-up of 15 months, the median 1year-OS of 89.3% 
[95%CI: 73.9; 95.8] placebo and 89.7% [95%CI: 80.4; 94.8] 
clonidine MBT. 
 
Conclusion: Clonidine MBT daily applied to the gum 
throughout CRT reduced the incidence of SOM and was well 
tolerated in HNC patients undergoing postoperative CRT. No 
significant systemic effects of clonidine were reported in the 
phase 2 study probably due to its low systemic levels. 
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Purpose or Objective: Specific objectives of the study were 
(i) to assess whether prophylactic exercise intervention 
prevented the worsening of jaw tightening that would be 
expected following radiotherapy (ii) to assess whether the 
Therabite® or wooden spatulas intervention improved 
patients’ QOL as measured using validated questionnaires; 
(iii) to assess issues around power for sample size 
calculations, compliance and practical aspects of running a 
full RCT in this group of patients and (iv) whether the 
intervention reduced the level of post-treatment clinical 
management/health care utilisation required by mouth 
cancer patients 
 
Material and Methods: All patients had some sense of 
subjective jaw tightening prior to study entry. Measurements 
of jaw opening and QOLs were taken pre and post 
radiotherapy 3 and 6 months. Patients were instructed to 
follow the 5-5-30 regimen daily, for 6 months. (5stretches, 
5times, 30 second hold). 
 
Results: 37 patients with stage 3/4 oral/oropharyngeal 
cancers were randomised to receive the therabite device and 
34 the wooden spatulas for jaw exercises. The study has 
shown that mouth openings had increased on average in both 
groups following the exercise intervention. There was no 
statistically significant difference between the two 
interventions. There were problems with compliance. Lessons 
learnt from the semi structured telephone interviews, (15 
patients) which would aid compliance included: (1) Allow 
patients to have more of a say in the exercise regimen ie 
reduce to 3 times a day. (2) Allow patients to take a variable 
break (up to 6 weeks) from the exercises when side effects of 
radiotherapy are at their worst. Mucositis, soreness and pain 
in mouth being reported during last few weeks and 4 weeks 
post radiotherapy. (3) More regular contact with the patients 
for encouragement and support. The study was designed to 
give an indication about the benefits of exercises and to 
inform feasibility to conduct a larger study 
 
Conclusion: Prophylactic exercises during and after 
radiotherapy treatment can ameliorate trismus for stage 3 
and 4 oral/oropharyngeal cancers. Keyword: Trismus, 
Radiotherapy This abstract presents independent research 
funded by the National Institute for Health Research (NIHR) 
under its Research for Patient Benefit (RfPB) Programme 
(Grant Ref No: PB-PG-0610-22317). The views expressed are 
those of the author(s) and not necessarily those of the NHS, 
the NIHR or the Department of Health. Sponsor: The Christie 
NHS Foundation Trust 
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Purpose or Objective: A prospective randomized multi-
centre phase II trial comparing standard IMRT (S-IMRT) to 3-
phase adaptive dose painting by numbers (DPBN) for head 
and neck cancer (HNC) is currently recruiting patients. Unlike 
the fact that the initial dose prescription was derived from a 
phase I trial, we observed an unacceptable rate of late 
mucosal ulceration using this dose prescription in the DPBN 
group. This made us change the dose prescription in two 
steps. This interim analysis reports on acute and late toxicity 
and local (LC), regional (RC) and distant control (DC) in 
almost half of the patients to be included. 
 
Material and Methods: From 2011, Q3 to 2015, Q3 53 
patients received primary radio(chemo)therapy for HNC. We 
report on 45 patients who have ended therapy for ≥ 3 
months. Patient, tumor and treatment characteristics can be 
found in Table 1  
